NCT05423262View on ClinicalTrials.gov

A Study of TRK-950 in Patients With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Solid TumorMelanoma
Interventions
BIOLOGICAL

TRK-950

5 or 10 mg/kg administered intravenously over 60 minutes (weekly)

BIOLOGICAL

TRK-950

10 mg/kg administered intravenously over 60 minutes (weekly)

BIOLOGICAL

TRK-950

20 mg/kg administered intravenously over 60 minutes (bi-weekly)

DRUG

Nivolumab

240 mg administered intravenously over 30 minutes (bi-weekly)

BIOLOGICAL

TRK-950

10 mg/kg administered Intravenously over 60 minutes (weekly)

Trial Locations (1)

Unknown

National Cancer Center Hospital, Chuo Ku

All Listed Sponsors
lead

Toray Industries, Inc

INDUSTRY